HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA D.S. Siegel; K. Weisel; A. Zahlten-Kumeli; R. Medhekar; S. Sapra; B. Ding; X. Leleu;

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS M.E.Z. Capra; M. Beksac; P.G. Richardson; A. Unal; P. Corradini; S. Delimpasi; Z. Gulbas; G. Mikala; A. Neylon; A. Symeonidis; S. Bringhen; P. Moreau; H.V. Velde; F. Campana; S.L. Guennec; I. Spicka;

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach; A. Nooka; O. Samoylova; C.P. Venner; T. Facon; A. Spencer; S.Z. Usmani; K. Weisel; M. Mateos; K. Kim; S. Grosicki; K. Suzuki; S. Delimpasi; M. Obreja; A. Zahlten-Kumeli;